covid
Buscar en
Allergologia et Immunopathologia
Toda la web
Inicio Allergologia et Immunopathologia Equivalence of a single saline nebulised dose of formoterol powder vs three dose...
Información de la revista
Vol. 36. Núm. 4.
Páginas 196-200 (agosto 2008)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
4656
Vol. 36. Núm. 4.
Páginas 196-200 (agosto 2008)
ORIGINAL ARTICLES
Acceso a texto completo
Equivalence of a single saline nebulised dose of formoterol powder vs three doses of nebulised Albuterol every twenty minutes in acute asthma in children: a suitable cost effective approach for developing nations
Visitas
4656
E. Rodrigueza, V. Veraa, A. Perez-Puigbob,
Autor para correspondencia
armandoapp@gmail.com

Correspondence: A. Perez-Puigbo MD Hospital de Clínicas y Urología Tamanaco Caracas. Venezuela Phone: 58-414-3222118.
, A. Capriles-Hulettc, S. Ferrob, J. Manriquea, J. Abated
a Hospital Pediátrico “Elías Toro”. Caracas. Venezuela
b Hospital de Clínicas y Urología Tamanaco. Caracas. Venezuela
c Centro Medico Docente La Trinidad. Caracas. Venezuela
d Research and Data Processing Inc. Caracas. Venezuela
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Tablas (2)
Table I. Wood-Downes score modified by authors*
Table II. Comparison between pre-treatment and post-treatment values
Mostrar másMostrar menos
Abstract
Background

An increase in asthma prevalence is reported from developed as well as developing nations, with rising costs from acute asthma and great expenditures to health care systems. Venezuela's Ministry of Health ambulatory facilities care for 80% or more of a mostly urban and impoverished population of 26 million inhabitants, registering close to a million acute asthma visits per year; a nebulised fixed fenoterol-ipratropium bromide combination (Berodual®, Boehringer-Ingelheim) in repeated dosing is the standard treatment.

Objectives

to simplify acute asthma care and management in a cost effective manner employing Formoterol Fumarate powder, a long acting beta agonist with immediate bronchodilator effects.

Methodology

Fifty acute asthmatic children (5-12 years old) were randomly assigned (25 patients in each group) to receive either a nebulised single dose (US $1.35) of two 12 μg Formoterol Fumarate capsules (Foradil® 12 μg/cap, Novartis Pharma AG, Basel, Switzerland) diluted in 2.5 ml of sterile saline solution; or 3 doses of Albuterol (US $ 6.73) every twenty minutes for one hour (Glaxo Smith Kline Albuterol ampoules, 2.5 mg/2.5 ml, at a dose of 0.15 mg/kg/dose, maximum dose 2.5 mg). Symptoms score, oxygen saturation and lung function testing were recorded before and one hour after commencing treatments.

Results

Both groups improved significantly on all parameters, except for FEV 1 in the Albuterol group.

Conclusions

Single dose nebulised Formoterol Fumarate (dry powder) in sterile saline solution, as depicted in this trial, is equivalent to three doses of Albuterol every twenty minutes for one hour in acute asthma in children, simplifying acute care management and at one fifth of medication costs. A pursuit of simpler and more cost effective approaches is found wanting in developing nations with depressed economies and unique cultural and socio-medical contexts; also, in countries where pharmaco-economics orients quality of health policies, novel approaches like this are worth exploring.

Key words:
Asthma
Children
Formoterol
Salbutamol
Cost-effectiveness
Developing countries
Texto completo
INTRODUCTION

Asthma faces tremendous challenges in developing nations and the Global Initiative for Asthma (GINA), well aware of these facts, encourages adaptations to particular needs; aspects of diagnosis, treatment and access to medication are but a few1. Acute asthma care has risen alarmingly for the last twenty years registering more than a million visits per year to the ambulatory network of the Ministry of Health of Venezuela, serving 80 % or more of a mostly urban and impoverished population of 26 million inhabitants2; this high morbidity falls second to entities like the “viral syndrome”, although ahead of diarrheal diseases and others. Similar situations are confronted by other developing nations and when compared, for example, to reports from the United States with roughly ten times the population and only twice the morbidity, the nature of the problem is underscored2.

Across the nation and for many years, delivery of this acute care has been in nebulised form, widely employing a fixed ipratoprium bromide/fenoterol combination (Berodual®, Boehringer-Ingelheim) in repeated dosing, thus allowing profitable use of our ample availability of nebulization devices2. Inhalation of Formoterol dry powder, a long acting beta-agonist with implicit immediate bronchodilator effect, has been found as effective as the short acting beta-agonists in the treatment of acute asthma as well as in rescue or needed use in asthma3–7; when used in a daily maintenance dose of 24μg for a year (Foradil®, Aerolizer®), no serious adverse effects have been detected in children8. However, very little information is available in relation to the use of nebulised Formoterol in the acute setting, a form of administration more suitably adapted to our medical and cultural context9–12. Recently (2007), the Federal Drug Administration (FDA), approved a Dey L.P. 20μg/vial of Formoterol Fumarate saline solution (Perforomist®) for maintenance use in COPD13,14; furthermore, over a period of approximately 10years we have developed an expertise in the use of nebulised Formoterol powder (Foradil®, Novartis Pharma AG, Basel Switzerland) in sterile saline solution9–12, a non-conventional form of administration found highly efficacious in relieving bronchospam when freshly prepared and immediately administered. This dilution of Foradil® has no influence on saline pH or osmolality and no differences are detected under the 40 × microscope (Tania Aguirre PhD, Investigaciones Especiales, Centro Medico Docente La Trinidad, Caracas, Venezuela); also microbiologic cultures, in standard media, have shown no growth of microorganisms (Departamento de Microbiologia, Laboratorio Autoanalitico del Instituto de Clinicas y Urología Tamanaco, Caracas, Venezuela) and its immediate administration after preparation obviates any practical considerations about stability. Our mentioned long expertise9–12 prompted us to carry out this study, blindly comparing a nebulised single dose of Formoterol Fumarate powder (two Foradil® 12μg capsules, 24μg in 2.5ml of sterile isotonic saline solution) vs. 0.1 % nebulised Albuterol ampoules (2.5mg/ 2ml solution, Glaxo Smith Kline) every twenty minutes, for one hour, in acute asthma in children.

METHODOLOGY

This is a prospective double-blind randomised controlled trial in children aged 5 to 12years with acute asthma exacerbations, between January 2006 and March 2007, admitted to the emergency room of the Hospital Pediátrico “Elias Toro” serving an impoverished area of Caracas. Eligibility criteria included a previous doctor's diagnosis of asthma in accordance with standard criteria, ability to perform a spirometric manoeuvre in the sitting position under enthusiastic coaching (Vitalograph® Alpha Spirometer) and absence of fever with no clinical evidence of superimposed bacterial infection (purulent bronchitis, otitis media, rales). The protocol was approved by the Institutional Review Board and Ethics Committee of the participating Institution and parent(s) or responsible party signed an informed consent before admission in study.

Children were excluded if presented with a first wheezing episode or one or more of coexisting cardiac, renal or other chronic pulmonary diseases.

After an initial medical evaluation by one of two research pediatricians (ER, VV), a trained nurse not related to the study, randomly assigned patients by a computer generated program, to receive either 3 doses of nebulised Albuterol every 20 minutes for one hour or a single dose of nebulised Formoterol Fumarate; final medical evaluations were performed by either research physician one hour after commencing treatments and neither pediatricians nor patients were aware of treatments received.

Treatments were prepared separately by the same nurse consisting of nebulised 0.1 % Albuterol ampoules (0.15mg/kg/dose, maximum 2.5mg/2.5ml) every 20 minutes for one hour or a single dose of nebulised Formoterol Fumarate powder (two Foradil® 12μg capsules, for a total of 24μg diluted in 2.5ml of sterile isotonic saline solution, freshly prepared and immediately administered), delivered via a PARI® PRONEB® turbo Nebulizer (Compressed Air without Oxygen) with face mask and allowing for a maximum nebulization time close to 10 minutes. Symptoms score (Modified Wood Downes's score, Table I), O2 saturation (Welch Allyn) and the best of 3 spirometric efforts (FEV1 and Peak Flow), at beginning and end of treatments (one hour), were considered for analysis; notes were taken of any medications administered in the previous 12 hours.

Table I.

Wood-Downes score modified by authors*

 
Respiratory Rate  Normal or up to 30 % > than mean for age  30-50 % > than mean respiratory rate for age  > 50 % than mean respiratory rate for age 
O2 Saturation  > 95 % in room air  92-95 % in room air  < 92 % in room air 
Auscultation  Normal or moderate wheezing at the end of expiration  Unequal breath sounds and intense wheezing during expiration  Breath sounds reduced and intense wheezing during inspiration or silent chest 
Use of accessory muscles  No  Intercostals, subcostals (mild to moderate)  Intercostals, subcostals, suprasternals (intense) or paradoxical breathing 
Conscious  Normal  Agitated  Agitated/Somnolence 
PEF (% of Predicted)  70-100%  50-70%  < 50 % 
*

Wood DW, Downes JJ, Locks HI. A clinical score for the diagnosis of respiratory failure. Amer J Dis Child 1972; 123: 227-9.

Statistical analysis

The sample size needed to detect meaningful statistical differences between comparison groups, with alpha = 5 % and beta = 20 %, is equal to 25 evaluable subjects in each group.

Homogeneity of variance test (Levene's test) showed that values obtained were not normally distributed, so, non-parametric tests were employed.

RESULTS

During the study period, 50 children were randomised and enrolled in the trial. One child in the Albuterol group, due to worsening asthma, was unable to complete the pulmonary function test at the end of treatment. There were no significant differences between groups for age, gender, height, weight, previous relevant medication or tobacco exposure. Significant improvements were noted for all parameters (Table II), except for FEV1 in the Albuterol group.

Table II.

Comparison between pre-treatment and post-treatment values

Albuterol
  Pre-Treatment  Post-Treatment  p value (Wilcoxon) 
HR/min  101 ± 14.9  106 ± 14  0.029 
RR/min  31.9 ± 4.08  27.4 ± 5.3  < 0.001 
SBP mm Hg  100.5 ± 11.1  104 ± 6.7  0.004 
DBP mm Hg  64.4 ± 5.61  66.5 ± 5.4  0.009 
Sat O2  95.2 ± 2.3  96.8 ± 2.1  < 0.001 
Score  10.1 ± 1.8  8.2 ± 2.1  < 0.001 
% FEV1  55.8 ± 30.9  56 ± 33.9  0.749 
% PF  40.6 ± 20.7  51.4 ± 27.9  0.004 
Formoterol
  Pre-Treatment  Post-Treatment  p value (Wilcoxon) 
HR/min  98.2 ± 12.4  99.3 ± 13.5  0.338 
RR/min  30.8 ± 6  24.88 ± 4.89  < 0.001 
SBP mm Hg  102.2 ± 8.93  104.8 ± 11.2  0.078 
DBP mm Hg  66.3 ± 5.9  67.7 ± 5.3  0.134 
Sat O2  94.5 ± 1.7  96.9 ± 1.8  < 0.001 
Score  10.5 ± 1.2  7 ± 1.7  < 0.001 
% FEV1  58 ± 31.7  67.8 ± 31.1  < 0.001 
% PF  47.2 ± 20.3  57.6 ± 24.5  < 0.001 

HR: heart rate; RR: respiratory rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; Sat O2: oxygen saturation; Score: clinical symptom score (modified from Downes); FEV1: maximum expiratory flow in one second % of predicted value; PF: peak flow: maximum peak flow% of predicted value.

DISCUSSION

The present worldwide tendency at the acute setting is to replace nebulised medications with either Metered Dose Inhalers (MDIs, with or without the use of spacers) or with medication in powder form1,17. Venezuela has developed a pattern of nebulised acute care over many years and changing it will entail, among other endeavours, intense and correspondingly widespread education efforts; also, a most likely future underutilisation of already existing nebulisation devices. Such an approach is not foreseeable to us, as a public health policy, in the very near future.

Considering the ample use of these nebulisation devices at ambulatory facilities of the Ministry of Health of Venezuela and, since Berodual® is not a widely employed therapy for acute asthma in many countries, we compared nebulised Formoterol Fumarate powder with current Albuterol recommendations. No doubt nebulisations can be used by persons of any age or with lack of coordination, thus increasing the therapeutic range of a drug, something also to bear in mind. Formoterol Fumarate dry powder at variable and multiple dosing has been compared to frequent and different doses of Albuterol in powder and/or in MDI form, and found as effective for acute bronchospasm3–7; at the 24μg dry powder daily maintenance dose (Foradil®, Aerolizer®) it has shown no serious adverse effects in children8. However, very little information exists for nebulised Formoterol Fumarate powder in acute asthma9–12, though an inhalation saline solution of 20μg/vial of Formoterol Fumarate for BID nebulisation in COPD has been recently developed by Dey L.P. (Perforomist®) and approved (2007) by the FDA13,14. Our high burden of acute asthma care2, the known fact that the greater expenditures for asthma come from hospitalisations and emergency visits1, our long and previous experience in the use of this non-conventional form of administration9–12, the entailed management simplification and significant cost savings (LOCATEL® chain drugstore, October 2007: Foradil® 2 capsules $ 1.35 vs. 3 ampoules of Albuterol GSK $ 6.73), and the fact that, to our knowledge, no available study has compared nebulised Formoterol Fumarate powder with nebulised Albuterol, all prompted us to carry out this study. Children with acute asthma experience difficulties with pulmonary function tests15; however, these functional measurements of airway obstruction do not necessarily correlate with other parameters, since different aspects of the disease are under scrutiny16. The lack of significant FEV1 improvement found after three doses of Albuterol in this study might very well fall under these premises and if higher doses were to be employed on such a heterogenous population, perhaps a better response would be found. As depicted in this trial, nebulised Formoterol Fumarate powder seems to be equivalent to 3 doses of nebulised Albuterol in children's acute asthma. A pursuit of simpler but also more cost-effective approaches is found wanting in developing nations with depressed economies and unique cultural and social contexts, but it is also worth considering for more affluent societies where pharmaco-economics approaches guide health budgets17. To orient public health policies and efficiently impact management of acute asthma, findings from this study need to be replicated in larger number of patients. In view of the reported controversial subsensitivity to Albuterol after employing long-acting bronchodilators, concomitant use of steroids should always be considered18.

REFERENCES
[1.]
Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2006. Available from: http://www.ginasthma.org
[2.]
E. Capriles, A. Do Campo, O. Verde, S. Pluchino, A. Capriles Hulett.
Children's asthma in the third world: an approach.
J Investig Allergol Clin Immunol, 16 (2006), pp. 11-18
[3.]
L. Avila-Castanon, B. Casas-Becerra, B.E. Del Rio-Navarro, Y. Velazquez-Armenta, J.J. Sierra-Monge.
Formoterol vs Albuterol administered via Tubuhaler® in emergency treatment of acute asthma in children.
Allergol et Immunopathol, 32 (2004), pp. 18-20
[4.]
W. Boonsawat, S. Charoebratanakul, C. Pothirat, K. Swanyawisuth, T. Seearamroongruang, T. Bengtsson, R. Brander, O. Selroos.
Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacers in patients with acute severe asthma.
Respr Med, 97 (2003), pp. 1067-1074
[5.]
K. Najafizadeh, H. Sohrab Pour, M. Ghadyanee, M. Shiehmorteza, M. Jamali, S. Majdzadeh.
A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma.
Emerg Med J, 24 (2007), pp. 317-321
[6.]
M. Lee-Wong, V. Chou, Y. Ogawa.
Formoterol fumarate inhalation powder vs albuterol nebulizer for the treatment of asthma in the acute care setting.
Ann Allergy Asthma Immunol, 100 (2008), pp. 164-252
[7.]
W. Berger.
The use of Formoterol in the treatment of asthma.
Ann Allergy Asthma Immunol, 97 (2006), pp. 24-33
[8.]
G. Bensch, W. Berger, B. Blokhin, A.L. Socolovsky, M.H. Thomson, M.D. Till, J. Castellague, G. Della Cioppa.
International Study Group on Foradil evaluation in Pediatric Asthma. One year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma.
Ann Allergy Asthma Immunol, 89 (2002), pp. 180-190
[9.]
Pérez Puigbó A, Capriles Hulett A, Verde O, Rodríguez G, Pérez Reggeti J. Una nueva forma de administración: Reporte preliminar, efecto broncodilatador inmediato de Formoterol en solución salina vía Nebulización. Abstract No. 13 XIII Congreso de la Sociedad Venezolana de Alergia, Asma e Inmunología. Caracas Junio de 2000.
[10.]
A. Pérez Puigbó, E. Capriles Behrens, L. Giannoni Delgado.
Nebulized Saline Solution of Dry Powder Formoterol is Useful for Acute Bronchospasm.
Arch Venez Farmacol Terap, 20 (2001), pp. 128-130
[11.]
A. Pérez Puigbó, A. Capriles, L. Giannoni, O. Verde, G. Rodríguez.
Una nueva alternativa terapéutica en el manejo del asma aguda (reporte preliminar).
Alergia, Asma e Inmunología, vol II (2000), pp. 73-76
[12.]
E. Rodriguez, V. Vera, A. Perez-Puigbo, A. Capriles-Hulett, J. Manrique, J. Abate, S. Ferro.
A descriptive non-inferiority comparative analysis of single dose nebulized Formoterol powder (Foradil 24 μg) in isotonic saline vs three doses of albuterol (2.5 mg ampules, GSK) every twenty minutes for children's acute asthma: a cost effective approach for developing nations.
World Allergy Congress,
[13.]
FDA approves Dey L.P.’s Perforomist® (Formoterol Fumarate) inhalation solution for maintenance treatment of COPD. Available from: http://www.medicalnewstoday.com. Respiratory/Asthma News, article date: 12 May 2007, accessed December 2007.
[14.]
Nelson HS, Zu Wallack R, Levine B, Kerwin EM, Denis-Mize K, Rinehart M. “Safety Profile of Formoterol Fumarate Delivered by Nebulization to COPD Patients” ATS meeting 2007;Abstract A11.
[15.]
M.H. Gorelick, M.W. Stevens, T. Schultz, P.W. Scribano.
Difficulty in obtaining peak expiratory flow measurements in children with acute asthma.
Pediatr Emerg Care, 20 (2004), pp. 22-26
[16.]
C. Ribeiro de Andrade, M.C. Duarte, P. Camargos.
Correlations between pulse oximetry and peak expiratory flow in acute asthma.
Braz J Med Biol Res, 40 (2007), pp. 485-490
[17.]
C. Cates.
Spacers and nebulisers for the delivery of beta agonist in non-life-threatening acute asthma.
Respiratory Medicine, 97 (2003), pp. 762-769
[18.]
J.P. Watson, R.A. Lewis.
Is asthma treatment affordable in developing countries?.
Thorax, 52 (1997), pp. 605-607
[19.]
B.J. Lipworth.
Airway subsenstivitiy with long-acting beta 2 agonists. Is there a cause for concern?.
Drug Safety, 16 (1997), pp. 295-308
Copyright © 2008. Sociedad Española de Inmunología Clínica y Alergología Pediátrica y Elsevier España, S.L.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aller.2020.05.005
No mostrar más